Review Article| Volume 32, ISSUE 3, P609-625, August 2016

Download started.


Vaccinations for the Older Adult


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kale S.S.
        • Ahuja N.
        • Yende S.
        • et al.
        Newman A.B. Cauley J.A. The epidemiology of aging. Springer, Dordecht (Netherlands)2012: 237-253
        • Taub D.D.
        • Longo D.L.
        Insights into thymic aging and regeneration.
        Immunol Rev. 2005; 205: 72-93
        • Lambert N.D.
        • Ovsyannikova I.G.
        • Pankratz V.S.
        • et al.
        Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach.
        Expert Rev Vaccines. 2012; 11: 985-994
        • McLaughlin J.M.
        • McGinnis J.J.
        • Tan L.
        • et al.
        Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013.
        J Prim Prev. 2015; 36: 259-273
        • Centers for Disease Control and Prevention
        Epidemiology and prevention of vaccine-preventable diseases.
        in: Hamborsky J. Kroger A. Wolfe S. 13th edition. Public Health Foundation, Washington, DC2015: 12
        • Thompson W.W.
        • Comanor L.
        • Shay D.K.
        Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease.
        J Infect Dis. 2006; 194: S82-S91
        • Smeeth L.
        • Thomas S.L.
        • Hall A.J.
        • et al.
        Risk of myocardial infarction and stroke after acute infection or vaccination.
        N Engl J Med. 2004; 351: 2611-2618
        • Nichol K.L.
        • Nordin J.
        • Mullooly J.
        • et al.
        Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.
        N Engl J Med. 2003; 348: 1322-1332
        • Phrommintikul A.
        • Kuanprasert S.
        • Wongcharoen W.
        • et al.
        Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome.
        Eur Heart J. 2011; 32: 1730-1735
        • Clar C.
        • Oseni Z.
        • Flowers N.
        • et al.
        Influenza vaccines for preventing cardiovascular disease.
        Cochrane Database Syst Rev. 2015; (CD005050)
        • Jefferson T.
        • Di Pietrantonj C.
        • Al-Ansary L.A.
        • et al.
        Vaccines for preventing influenza in the elderly.
        Cochrane Database Syst Rev. 2010; (CD004876)
        • Goodwin K.
        • Viboud C.
        • Simonsen L.
        Antibody response to influenza vaccination in the elderly: a quantitative review.
        Vaccine. 2006; 24: 1159-1169
        • Keitel W.A.
        • Atmar R.L.
        • Cate T.R.
        • et al.
        Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons.
        Arch Intern Med. 2006; 166: 1121-1127
        • Nace D.A.
        • Len C.J.
        • Ross T.M.
        • et al.
        Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
        J Infect Dis. 2015; 211: 1915-1924
        • DiazGranados C.A.
        • Dunning A.J.
        • Jordanov E.
        • et al.
        High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season.
        Vaccine. 2013; 31: 861-866
        • DiazGranados C.A.
        • Dunning A.J.
        • Kimmel M.
        • et al.
        Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
        N Engl J Med. 2014; 371: 635-645
        • Izurieta H.S.
        • Thadani N.
        • Shay D.K.
        • et al.
        Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
        Lancet Infect Dis. 2015; 15: 293-300
      1. Registration: NCT01815268.

      2. FLUAD [package insert]. Cambridge, MA: Novartis Vaccines and Diagnostics, Inc.; 2015.

        • Della Cioppa G.
        • Nicolay U.
        • Lindert K.
        • et al.
        Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults.
        Human Vaccines & Immunotherapeutics. 2012; 8: 216-227
      3. Centers for Disease Control and Prevention. Influenza (flu). 2015. Available at: Accessed September 18, 2015.

        • Osterholm M.T.
        • Kelley N.S.
        • Sommer A.
        • et al.
        Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.
        Lancet Infect Dis. 2012; 12: 36-44
        • Grohskopf L.A.
        • Sokolow L.Z.
        • Olsen S.J.
        • et al.
        Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-16 influenza season.
        MMWR Morb Mortal Wkly Rep. 2015; 64: 818-825
      4. Centers for Disease Control and Prevention. Adult immunization schedules. United States, 2015. Available at: Accessed September 15, 2015.

      5. Office of Disease Prevention and Health Promotion. Increase the percentage of health care personnel who are vaccinated annually against seasonal influenza. 2013. Available at: Accessed October 21, 2015.

        • Black C.L.
        • Yue X.
        • Ball S.W.
        • et al.
        Influenza vaccination coverage among health care personnel – United States, 2013-14 influenza season.
        MMWR Morb Mortal Wkly Rep. 2014; 63: 805-811
        • Ahmed F.
        • Lindley M.C.
        • Allred N.
        • et al.
        Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence.
        Clin Infect Dis. 2014; 58: 50-57
        • Griffin M.R.
        Influenza vaccination of healthcare workers: making the grade for action.
        Clin Infect Dis. 2014; 58: 58-60
        • Potter J.
        • Stott D.J.
        • Roberts M.A.
        • et al.
        Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients.
        J Infect Dis. 1997; 175: 1-6
        • National Vaccine Advisory Committee
        Strategies to achieve the Healthy People 2020 annual influenza vaccine coverage goal for health-care personnel: recommendations from the National Vaccine Advisory Committee.
        Public Health Rep. 2013; 128: 7-25
      6. Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2009: with special feature on medical technology. Hyattsville (MD): Department of Health and Human Services; 2010.

        • World Health Organization
        23-valent pneumococcal polysaccharide vaccine: WHO position paper.
        Wkly Epidemiol Rec. 2008; 83: 373-384
        • Curcio D.
        • Cane A.
        • Isturiz R.
        Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence.
        Int J Infect Dis. 2015; 37: 30-35
        • Moberley S.
        • Holden J.
        • Tatham D.P.
        • et al.
        Vaccines for preventing pneumococcal infection in adults.
        Cochrane Database Syst Rev. 2013; (CD000422)
        • Musher D.M.
        Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?.
        Clin Infect Dis. 2012; 55: 265-267
        • Williams W.W.
        • Lu P.J.
        • O’Halloran A.
        • et al.
        Vaccination coverage among adults, excluding influenza vaccination – United States, 2013.
        MMWR Morb Mortal Wkly Rep. 2015; 64: 95-102
        • Pletz M.W.
        • Maus U.
        • Krug N.
        • et al.
        Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
        Int J Antimicrob Agents. 2008; 32: 199-206
        • Centers for Disease Control and Prevention
        Manual for the surveillance of vaccine-preventable diseases.
        Centers for Disease Control and Prevention, Atlanta (GA)2012
        • Moore M.R.
        • Link-Gelles R.
        • Schaffner W.
        • et al.
        Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
        Lancet Infect Dis. 2015; 15: 301-309
        • Bonten M.J.
        • Huijts S.M.
        • Bolkenbaas M.
        • et al.
        Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
        N Engl J Med. 2015; 372: 1114-1125
        • Centers for Disease Control and Prevention
        Tetanus surveillance-United States, 2001-2008.
        MMWR Morb Mortal Wkly Rep. 2011; 60: 365-369
        • McQuillan G.M.
        • Kruszon-Moran D.
        • Deforest A.
        • et al.
        Serologic immunity to diphtheria and tetanus in the United States.
        Ann Intern Med. 2002; 136: 660-666
      7. Centers for Disease Control and Prevention. Pertussis (whooping cough) surveillance and reporting. Available at: Accessed October 19, 2015.

        • Skoff T.H.
        • Kenyon C.
        • Cocoros N.
        • et al.
        Sources of infant pertussis infections in the United States.
        Pediatrics. 2015; 136: 635-641
        • Grizas A.P.
        • Camenga D.
        • Vázquez M.
        Cocooning: a concept to protect young children from infectious diseases.
        Curr Opin Pediatr. 2012; 24: 92-97
      8. Centers for Disease Control and Prevention. Combined Tdap vaccine. 2014. Available at: Accessed October 19, 2015.